Mitomycin ophthalmic

Drug Profile

Mitomycin ophthalmic

Alternative Names: Mitomycin-c ophthalmic solution - Mobius Therapeutics; Mitosol

Latest Information Update: 09 Sep 2015

Price : $50

At a glance

  • Originator Mobius Therapeutics
  • Class Antineoplastics; Aziridines; Carbamates; Cytostatic antibiotics; Glucosidases; Indoles; Recombinant proteins; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Corneal disorders; Recurrent pterygium; Glaucoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma
  • Preregistration Corneal disorders; Recurrent pterygium

Most Recent Events

  • 09 Sep 2015 Mitomycin opthalmic is still awaiting approval for corneal disorders in USA
  • 09 Jul 2012 Launched for Glaucoma in USA (Intraocular) - First global launch
  • 09 Feb 2012 Registered for Glaucoma in USA (Intraocular) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top